Howe & Rusling’s ProQR Therapeutics PRQR Stock Holding History

Howe & Rusling’s Portfolio PRQR Stock Details PRQR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-27	Closed	–	–	1053
2015 Q3	$0	Hold	27	–	–	﹤0.01%	1061
2015 Q2	$0	Buy	+27	New	+$509	﹤0.01%	1100

Other funds holding PRQR

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

HCMT

Highland Capital Management (Texas) Dallas, Texas $39M AUM

Howe & Rusling's PRQR Position: Q4 2015 in Review

Howe & Rusling sold out of ProQR Therapeutics (PRQR) in Q4 2015, closing a stake of 27 shares.

Howe & Rusling first reported a position in PRQR in Q2 2015 and held it in 2 quarters. The position peaked at $0 in Q3 2015. 32 funds tracked by Wall St. Rank hold PRQR as of Q4 2015.

Howe & Rusling reported no remaining ProQR Therapeutics position as of Q4 2015 after selling out during the quarter.
Howe & Rusling sold 27 ProQR Therapeutics shares in Q4 2015.
Howe & Rusling first reported a position in ProQR Therapeutics in Q2 2015 and held it in 2 quarters.
Howe & Rusling's ProQR Therapeutics position peaked at $0 in Q3 2015.
32 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q4 2015.

Based on Howe & Rusling's 13F filing for Q4 2015, filed 11 Feb 2016.